Table 2.
Demographic and clinicopathological characteristics of CRC patient and normal groups.
| Clinical Parameter | Total (n = 113) (%) | Adjuvant Group (n = 42) (%) | Metastatic Group (n = 71) (%) | Normal (n = 20) (%) |
|---|---|---|---|---|
| Age (years) | ||||
| Mean ± SD | 67.0 ± 9.7 | 69.5 ± 8.7 | 65.5 ± 10 | 58.9 (±9.0) |
| Median, range | 68, 44–87 | 70.5, 47–87 | 67, 44–85 | 59, 43–76 |
| Gender | ||||
| Male | 78 (69%) | 30 (71.4%) | 48 (67.6%) | 11 (55%) |
| Female | 35 (31%) | 12 (28.6%) | 23 (32.4%) | 9 (45%) |
| BMI | ||||
| <18.5 | 2 (1.8%) | 0 | 2 (2.8%) | 0 |
| 18.5–24.9 | 12 (10.6%) | 6 (14.3%) | 6 (8.5%) | 8 (40%) |
| 25–29.9 | 35 (31%) | 24 (57.1%) | 11 (15.5%) | 6 (30%) |
| ≥30 | 13 (11.5%) | 11 (26.2%) | 2 (2.8%) | 3 (15%) |
| Not available | 51 (45.1%) | 1 (2.4%) | 50 (70.4%) | 3 (15%) |
| Cancer location | ||||
| R | 19 (16.8%) | 13 (31%) | 6 (8.5%) | |
| A | 7 (6.2%) | 4 (9.5%) | 3 (4.2%) | |
| S | 28 (24.8%) | 18 (42.9%) | 10 (14.1%) | |
| T | 2 (1.8%) | 2 (4.8%) | 0 | |
| D | 3 (2.7%) | 3 (7.1%) | 0 | |
| C | 4 (3.5%) | 2 (4.8%) | 2 (2.8%) | |
| Νot available | 50 (44.2%) | 0 | 50 (70.4%) | |
| Dukes classification | ||||
| A | 14 (12.4%) | 14 (33.3%) | 0 | |
| B | 14 (12.4%) | 13 (31%) | 0 | |
| C | 13 (11.5%) | 13 (31%) | 0 | |
| D | 69 (61%) | 0 | 71 (100%) | |
| Not available | 3 (2.7%) | 2 (4.8%) | 0 | |
| Astler–Coller classification | ||||
| A | 2 (1.8%) | 2 (4.8%) | 0 | |
| B1 | 12 (10.6%) | 12 (28.6%) | 0 | |
| B2 | 13 (11.5%) | 13 (31%) | 0 | |
| B3 | 0 | 0 | 0 | |
| C1 | 1 (0.9%) | 1 (2.4%) | 0 | |
| C2 | 12 (10.6%) | 12 (28.6%) | 0 | |
| C3 | 0 | 0 | 0 | |
| D | 71 (62.8%) | 0 | 71(100%) | |
| Not available | 2 (1.8%) | 2 (4.8%) | 0 | |
| Stage | ||||
| Ι | 15 (13.3%) | 15 (35.7%) | 0 | |
| ΙΙ | 13 (11.5%) | 13 (31%) | 0 | |
| ΙΙΙ | 13 (11.5%) | 13 (31%) | 0 | |
| IV | 71 (62.8%) | 0 | 71(100%) | |
| Not available | 1 (0.9%) | 1 (2.4%) | 0 | |
| Grade | ||||
| 1 | 41 (36.3%) | 18 (42.9%) | 14 (19.7%) | |
| 2 | 50 (44.2%) | 18 (42.9%) | 41 (57.7%) | |
| 3 | 12 (10.6%) | 5 (11.9%) | 7 (9.9%) | |
| Not available | 10 (8.9%) | 1 (2.4%) | 9 (12.7%) | |
| Tumor size | ||||
| T1 | 3 (2.7%) | 3 (7.15%) | 0 | |
| T2 | 24 (21.2%) | 13 (30.95%) | 11 (15.5%) | |
| T3 | 66 (58.4%) | 21 (50%) | 45 (63.4%) | |
| T4 | 12 (10.6%) | 4 (9.5%) | 8 (11.3%) | |
| Not available | 8 (7.1%) | 1 (2.4%) | 7 (9.8%) | |
| LN status | ||||
| N0 | 52 (46%) | 27 (64.3%) | 0 | |
| N1 | 25 (22.1%) | 9 (21.4%) | 28 (39.4%) | |
| N2 | 26 (23%) | 4 (9.5%) | 35 (49.3%) | |
| Not available | 10 (8.9%) | 2 (4.8%) | 8 (11.3%) | |
| Metastatic site | ||||
| Lung | 21 (18.6%) | 0 | 21 (29.6%) | |
| Liver | 55 (48.7%) | 0 | 55 (77.5%) | |
| Pancreas | 1 (0.9%) | 0 | 1 (1.4%) | |
| Bone | 1 (0.9%) | 0 | 1 (1.4%) | |
| Peritoneum | 10 (8.9%) | 0 | 10 (14%) | |
| Brain | 2 (1.8%) | 0 | 2 (2.8%) | |
| Testis | 1 (0.9%) | 0 | 1 (1.4%) | |
| Uterus | 1 (0.9%) | 0 | 1 (1.4%) |
A: ascending; BMI: body mass index; C: cecum; D: descending; LN: lymph node; R: rectum; S: sigmoid; T = transverse.